Healthcare Industry News: Pulse Oximetry
News Release - March 20, 2007
Atom Medical to Incorporate Masimo Rainbow SET Technology Into Atom's Neonatal and Premature Infant Product LinesMasimo Rainbow SET Is the First and Only Way for Clinicians to Continuously and Noninvasively Monitor Their Patients' Carboxyhemoglobin, Methemoglobin, and Oxyhemoglobin Saturation as Well as Pulse Rate and Perfusion Index
IRVINE, Calif., March 20 (HSMN NewsFeed) -- Atom Medical Corporation today announced that it has entered into a new agreement with Masimo that will allow it to incorporate Masimo Rainbow SET technology into its neonatal and premature infant product lines. Masimo Rainbow SET is a breakthrough noninvasive blood constituent monitoring platform that has the promise of measuring many blood constituents that previously required invasive procedures. Masimo Rainbow SET's initial application is Pulse CO-Oximetry, the first and only technology platform capable of continuously and noninvasively measuring carboxyhemoglobin (SpCO) and methemoglobin (SpMet), in addition to oxyhemoglobin (SpO2), perfusion index (PI), Pleth Variability Index (PVI) and pulse rate.
Masimo Rainbow SET uses multiple (7+) wavelengths of light housed in a single, simple-to-apply sensor to accurately determine levels of SpCO and SpMet -- two critical dyshemoglobins, that if not monitored and treated, has proven to increase morbidity and mortality in a broad range of clinical settings. This gives clinicians the ability to accurately determine their patients' true oxygenation status, allowing for more precise and timely diagnosis and treatment.
Built on the gold-standard Read-Through Motion and Low Perfusion Masimo SET technology, Masimo Rainbow SET has been designed as an upgradeable technology platform. Masimo scientists are currently at work using the data delivered by Rainbow's multiple wavelengths of light to qualify additional noninvasive parameters, such as total hemoglobin (SpHb), which are anticipated to be able to be field-installed on Rainbow-ready monitoring devices through a simple software upgrade, so clinicians can easily purchase and add them when they become available.
Barry Matsubara, Chairman and Chief Executive Officer of Atom stated; "We have enjoyed a long partnership with Masimo. The main goal of this partnership has been to improve the care of patients our products touch. We entered into this partnership with Masimo nearly 10 years ago because we believed Masimo had made a tremendous stride with its Masimo SET Read-Through Motion and Low Perfusion technology. Today, Masimo SET is clearly considered the gold standard in Pulse Oximetry and has been shown to improve patient care across the globe. We believe that the new Rainbow Technology will have similar impact, with the ability to measure carboxyhemoglobin and methemoglobin noninvasively. We are looking forward to be one of the first companies to provide our customers with this life saving monitoring technology."
Joe E. Kiani, Chairman and CEO of Masimo stated; "We are very happy to expand our long and productive relationship with Atom to bring Masimo Rainbow SET's new monitoring capabilities to neonatal and infant care -- where Atom excels. This has always been an important segment of the market for Masimo. Not only because they are the most challenging patient population, but because having the ability to make an impact on neonates' lives provides a longer benefit than for any other patient population. We continue to focus our efforts heavily in neonatal and infant monitoring as evidenced by innovations like our Blue sensor, which is specially designed to monitor cyanotic babies with very low oxygen saturation and children with congenital heart defects, and our Newborn sensor designed for newborn resuscitation and examination."
About Atom Medical Corporation
Atom Medical has an active and strong sales network and is made up of over 50 overseas distributors who market, sell, and service Atom's name brand perinatal products to hospitals and clinicians in over 90 countries. In addition, long term relationships with over ten international medical manufacturers ensure that local clinical needs can be met with the latest imported medical products. Atom Medical will continue its commitment to providing the finest in medical products and care to its worldwide customers.
Masimo develops innovative monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion Pulse Oximetry, known as SET, and with it virtually eliminated false alarms and increased Pulse Oximetry's ability to detect life-threatening events. More than 100 independent clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations -- establishing the technology as the "gold standard" Pulse Oximetry and substantially contributing to improved patient outcomes. In 2005 Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.
Masimo, SET, Signal Extraction Technology, Radical, Radical-7, Rad57, APOD, and Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. Rainbow, SpCO, SpMet, SpHb, PVI, and Pulse CO-Oximeter are trademarks of Masimo Corp.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.